



- (51) **International Patent Classification:**
C12N 15/11 (2006.01) *A61P 25/08* (2006.01)
- (21) **International Application Number:**
PCT/US2024/027823
- (22) **International Filing Date:**
03 May 2024 (03.05.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/499,779 03 May 2023 (03.05.2023) US
- (71) **Applicant:** **STOKE THERAPEUTICS, INC.** [US/US];
45 Wiggins Avenue, Bedford, Massachusetts 01730 (US).
- (72) **Inventors:** **AZNAREZ, Isabel**; c/o Stoke Therapeutics,
Inc., 45 Wiggins Avenue, Bedford, Massachusetts 01730
(US). **DIVAKARAMENON, Sethumadhavan**; c/o Stoke
Therapeutics, Inc., 45 Wiggins Avenue, Bedford, Massa-
chusetts 01730 (US). **SCHARNER, Juergen**; c/o Stoke
Therapeutics, Inc., 45 Wiggins Avenue, Bedford, Massa-
chusetts 01730 (US). **JEON, Hyun-Yong**; c/o Stoke Ther-
apeutics, Inc., 45 Wiggins Avenue, Bedford, Massachusetts
01730 (US).
- (74) **Agent:** **NIP, Lisa**; Wilson Sonsini Goodrich & Rosati, 650
Page Mill Road, Palo Alto, California 94304 (US).
- (81) **Designated States** (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

- (54) **Title:** COMPOUNDS AND METHODS FOR TREATING HUMAN SUBJECTS




FIG. 9

- (57) **Abstract:** Described herein are compounds and methods that can be used to treat a disease or condition by increasing SYNGAP1 protein.